Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells

Cancer Letters

Volumn 314, Issue 2, 2012, Pages 147-154

  Kim, Sangmin ^a   Han, Jeonghun ^a   Lee, Se Kyung ^a   Koo, Minyoung ^a   Cho, Dong Hui ^a   Bae, Soo Youn ^b   Choi, Min Young ^a   Kim, Jee Soo ^a   Kim, Jung Han ^a   Choe, Jun Ho ^a   Yang, Jung Hyun ^b   Nam, Seok Jin ^a   Lee, Jeong Eon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

Author keywords

EGF signaling; MMP 9; Smad3; Smad7

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN INHIBITOR; SMAD7 PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; UO 126; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA(1,9 CD)PYRAZOL 6(2H) ONE; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; MESSENGER RNA; NITRILE; SMAD3 PROTEIN; SMAD3 PROTEIN, HUMAN; SMAD7 PROTEIN, HUMAN;

ADENOVIRUS; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; BREAST TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; GENETICS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANTHRACENES; BREAST NEOPLASMS; BUTADIENES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 9; NITRILES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84866031555     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.024     Document Type: Article

References (37)

1. N. Normanno, A. De Luca, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, A. Carotenuto, G. De Feo, F. Caponigro, D.S. Salomon, Epidermal growth factor receptor (EGFR) signaling in cancer, Gene 366 (2006) 2-16.
2. M.J. Wieduwilt, M.M. Moasser, The epidermal growth factor receptor family: biology driving targeted therapeutics, Cell. Mol. Life Sci. 65 (2008) 1566-1584.
3. D.S. Salomon, R. Brandt, F. Ciardiello, N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies, Crit. Rev. Oncol. Hematol. 19 (1995) 183-232.
4. L.N. Klapper, M.H. Kirschbaum, M. Sela, Y. Yarden, Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors, Adv. Cancer Res. 77 (2000) 25-79.
5. A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, D.J. Leahy, M.A. Lemmon, M.X. Sliwkowski, C.W. Ward, S. Yokoyama, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors, Mol. Cell 12 (2003) 541-552.
6. D.W. Leaman, S. Leung, X. Li, G.R. Stark, Regulation of STATdependent pathways by growth factors and cytokines, FASEB J. 10 (1996) 1578-1588.
7. G. Song, G. Ouyang, S. Bao, The activation of Akt/PKB signaling pathway and cell survival, J. Cell. Mol. Med. 9 (2005) 59-71.
8. G.L. Johnson, H.G. Dohlman, L.M. Graves, MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression, Curr. Opin. Chem. Biol. 9 (2005) 325-331.
9. S. Kim, J.H. Choi, H.I. Lim, S.K. Lee, W.W. Kim, S. Cho, J.S. Kim, J.H. Kim, J.H. Choe, S.J. Nam, J.E. Lee, J.H. Yang, EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line, Cell. Signal. 21 (2009) 892-898.
10. O.c. P, H. Modjtahedi, P. Rhys-Evans, W.J. Court, G.M. Box, S.A. Eccles, Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells, Cancer Res. 60 (2000) 1121-1128.
11. B. Heissig, K. Hattori, M. Friedrich, S. Rafii, Z. Werb, Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases, Curr. Opin. Hematol. 10 (2003) 136-141.
12. M. Egeblad, Z. Werb, New functions for the matrix metalloproteinases in cancer progression, Nat. Rev. Cancer 2 (2002) 161-174.
13. G. Bergers, L.M. Coussens, Extrinsic regulators of epithelial tumor progression: metalloproteinases, Curr. Opin. Genet. Dev. 10 (2000) 120-127.
14. M. Bjorklund, E. Koivunen, Gelatinase-mediated migration and invasion of cancer cells, Biochim. Biophys. Acta 1755 (2005) 37-69.
15. M. Nakajima, D.R. Welch, D.M. Wynn, T. Tsuruo, G.L. Nicolson, Serum and plasma M(r) 92, 000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma, Cancer Res. 53 (1993) 5802-5807.
16. S.B. Kondapaka, R. Fridman, K.B. Reddy, Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells, Int. J. Cancer 70 (1997) 722-726.
17. T. Okamoto, S. Takahashi, E. Nakamura, K. Nagaya, T. Hayashi, K. Fujieda, Transforming growth factor-beta1 induces matrix metalloproteinase-9 expression in human meningeal cells via ERK and Smad pathways, Biochem. Biophys. Res. Commun. 383 (2009) 475-479.
18. A.B. Roberts, A. Russo, A. Felici, K.C. Flanders, Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta, Ann. N. Y. Acad. Sci. 995 (2003) 1-10.
19. M. Deckers, M. van Dinther, J. Buijs, I. Que, C. Lowik, G. van der Pluijm, P. ten Dijke, The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells, Cancer Res. 66 (2006) 2202-2209.
20. M. Afrakhte, A. Moren, S. Jossan, S. Itoh, K. Sampath, B. Westermark, C.H. Heldin, N.E. Heldin, P. ten Dijke, Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members, Biochem. Biophys. Res. Commun. 249 (1998) 505-511.
21. T. Pawson, J.D. Scott, Signaling through scaffold, anchoring, and adaptor proteins, Science 278 (1997) 2075-2080.
22. H. Azuma, S. Ehata, H. Miyazaki, T. Watabe, O. Maruyama, T. Imamura, T. Sakamoto, S. Kiyama, Y. Kiyama, T. Ubai, T. Inamoto, S. Takahara, Y. Itoh, Y. Otsuki, Y. Katsuoka, K. Miyazono, S. Horie, Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells, J. Natl. Cancer Inst. 97 (2005) 1734-1746.
23. G. von Gersdorff, K. Susztak, F. Rezvani, M. Bitzer, D. Liang, E.P. Bottinger, Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta, J. Biol. Chem. 275 (2000) 11320-11326.
24. L. Ulloa, J. Doody, J. Massague, Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway, Nature 397 (1999) 710-713.
25. Z. Lu, S. Ghosh, Z. Wang, T. Hunter, Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion, Cancer Cell. 4 (2003) 499-515.
26. S.M. Ellerbroek, L.G. Hudson, M.S. Stack, Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion, Int. J. Cancer 78 (1998) 331-337.
27. J. Carcamo, A. Zentella, J. Massague, Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex, Mol. Cell. Biol. 15 (1995) 1573-1581.
28. M.P. de Caestecker, W.T. Parks, C.J. Frank, P. Castagnino, D.P. Bottaro, A.B. Roberts, R.J. Lechleider, Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases, Genes Dev. 12 (1998) 1587-1592.
29. D.L. Crowe, K.J. Tsang, B. Shemirani, Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression, Neoplasia 3 (2001) 27-32.
30. D.L. Crowe, T.N. Brown, Transcriptional inhibition of matrix metalloproteinase 9 (MMP-9) activity by a c-fos/estrogen receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion, Neoplasia 1 (1999) 368-372.
31. J. Kleeff, T. Ishiwata, H. Maruyama, H. Friess, P. Truong, M.W. Buchler, D. Falb, M. Korc, The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer, Oncogene 18 (1999) 5363-5372.
32. Y.H. Kim, H.S. Lee, H.J. Lee, K. Hur, W.H. Kim, Y.J. Bang, S.J. Kim, K.U. Lee, K.J. Choe, H.K. Yang, Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas, Ann. Oncol. 15 (2004) 574-580.
33. J.L. Boulay, G. Mild, J. Reuter, M. Lagrange, L. Terracciano, A. Lowy, U. Laffer, B. Orth, U. Metzger, B. Stamm, S. Martinoli, R. Herrmann, C. Rochlitz, Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7, Genes Chromosom. Cancer 31 (2001) 240-247.
34. Y. Kang, W. He, S. Tulley, G.P. Gupta, I. Serganova, C.R. Chen, K. Manova-Todorova, R. Blasberg, W.L. Gerald, J. Massague, Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway, Proc. Natl Acad. Sci. USA 102 (2005) 13909-13914.
35. D. Javelaud, K.S. Mohammad, C.R. McKenna, P. Fournier, F. Luciani, M. Niewolna, J. Andre, V. Delmas, L. Larue, T.A. Guise, A. Mauviel, Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis, Cancer Res. 67 (2007) 2317-2324.
36. D. Javelaud, V. Delmas, M. Moller, P. Sextius, J. Andre, S. Menashi, L. Larue, A. Mauviel, Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo, Oncogene 24 (2005) 7624-7629.
37. Y. Mori, S.J. Chen, J. Varga, Modulation of endogenous smad expression in normal skin fibroblasts by transforming growth factor-b, Exp. Cell Res. 258 (2000) 374-383.